These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 31160476)

  • 1. Nivolumab-Associated Acute Demyelinating Encephalitis: A Case Report and Literature Review.
    Zafar Z; Vogler C; Hudali T; Bhattarai M
    Clin Med Res; 2019 Jun; 17(1-2):29-33. PubMed ID: 31160476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple nivolumab-induced CNS demyelination with spontaneous resolution in an asymptomatic metastatic melanoma patient.
    Pillonel V; Dunet V; Hottinger AF; Berthod G; Schiappacasse L; Peters S; Michielin O; Aedo-Lopez V
    J Immunother Cancer; 2019 Dec; 7(1):336. PubMed ID: 31791418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report.
    Kopecký J; Kubeček O; Geryk T; Slováčková B; Hoffmann P; Žiaran M; Priester P
    J Med Case Rep; 2018 Sep; 12(1):262. PubMed ID: 30217214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoimmune-related encephalitis during treatment with nivolumab for advanced head and neck cancer: a case report.
    Guidi A; Violati M; Blasi M; Ferrari E; Luciani A; Codecà C; Ferrari D
    Tumori; 2020 Dec; 106(6):NP23-NP28. PubMed ID: 32851941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
    Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
    Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nivolumab-ipilimumab combination therapy-induced seronegative encephalitis; rapid response to steroid plus intravenous immunoglobulin (IVIG) treatment.
    Bir Yucel K; Sutcuoglu O; Yazıcı O; Yıldız Y; Şenol E; Uner A
    J Oncol Pharm Pract; 2023 Apr; 29(3):760-763. PubMed ID: 35938177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Case Report of Steroid Responsive Nivolumab-Induced Encephalitis.
    Richard K; Weslow J; Porcella SL; Nanjappa S
    Cancer Control; 2017; 24(5):1073274817729069. PubMed ID: 28975824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Very high-dose methylprednisolone for treatment of nivolumab-induced limbic encephalitis: A case report.
    Taillefer VT; Pigeon M; Chen M; Larochelle C; Florescu M; Bélanger K; Adam JP
    J Oncol Pharm Pract; 2020 Sep; 26(6):1538-1543. PubMed ID: 32063105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glial fibrillary acidic protein (GFAP) associated autoimmune meningoencephalitis in a patient receiving nivolumab.
    Kapadia RK; Ney DE; Hannan M; Farley M; Pastula DM; Piquet AL
    J Neuroimmunol; 2020 Jul; 344():577259. PubMed ID: 32416558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Encephalitis in a patient with hypopharynx cancer treated with immune checkpoint inhibitors and radiotherapy: a case report and review of the literature.
    Kang Y; Zhen H; Ma N; Zhao H; Cao B
    J Cancer Res Clin Oncol; 2023 Nov; 149(17):16239-16246. PubMed ID: 37676267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoimmune encephalitis related to nivolumab followed by tumor regression.
    Mysler SJ; Perazzo F; Mandó P
    Medicina (B Aires); 2023; 83(3):479-483. PubMed ID: 37379548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer.
    Williams TJ; Benavides DR; Patrice KA; Dalmau JO; de Ávila AL; Le DT; Lipson EJ; Probasco JC; Mowry EM
    JAMA Neurol; 2016 Aug; 73(8):928-33. PubMed ID: 27271951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subacute CNS Demyelination after Treatment with Nivolumab for Melanoma.
    Maurice C; Schneider R; Kiehl TR; Bavi P; Roehrl MH; Mason WP; Hogg D
    Cancer Immunol Res; 2015 Dec; 3(12):1299-302. PubMed ID: 26419960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nivolumab-related severe thrombocytopenia in a patient with relapsed lung adenocarcinoma: a case report and review of the literature.
    Hasegawa T; Ozaki Y; Inoue T; Watanabe Y; Fukuhara M; Yamaura T; Muto S; Okabe N; Higuchi M; Shio Y; Suzuki H
    J Med Case Rep; 2019 Oct; 13(1):316. PubMed ID: 31647029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with pembrolizumab after hypersensitivity reaction to nivolumab in a patient with hepatocellular carcinoma.
    Choi B; McBride A; Scott AJ
    Am J Health Syst Pharm; 2019 Oct; 76(21):1749-1752. PubMed ID: 31612928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A case of meningoencephalitis that developed during nivolumab use].
    Suzuki Y; Sakurai K; Uchino K; Inoue T; Takahashi T; Hasegawa Y; Yamano Y
    Nihon Ronen Igakkai Zasshi; 2021; 58(4):624-629. PubMed ID: 34880182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint inhibitor therapy-associated encephalitis: a case series and review of the literature.
    Stuby J; Herren T; Schwegler Naumburger G; Papet C; Rudiger A
    Swiss Med Wkly; 2020 Nov; 150():w20377. PubMed ID: 33232507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report.
    Koda R; Watanabe H; Tsuchida M; Iino N; Suzuki K; Hasegawa G; Imai N; Narita I
    BMC Nephrol; 2018 Feb; 19(1):48. PubMed ID: 29486725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progressive Multifocal Leukoencephalopathy after Treatment with Nivolumab.
    Martinot M; Ahle G; Petrosyan I; Martinez C; Gorun DM; Mohseni-Zadeh M; Fafi-Kremer S; Tebacher-Alt M
    Emerg Infect Dis; 2018 Aug; 24(8):1594-1596. PubMed ID: 30016251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.
    Tan I; Malinzak M; Salama AKS
    J Immunother Cancer; 2018 Jul; 6(1):77. PubMed ID: 30064495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.